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Treatments for Hyperemesis Gravidarum and Nausea and Vomiting in Pregnancy: A 
Systematic Review  
KEY POINTS 
Question: Which interventions are associated with improved symptoms of nausea and 
vomiting in pregnancy or hyperemesis gravidarum? 
Findings: Ginger, vitamin B6, antihistamines, metoclopramide (mild symptoms) and 
pyridoxine-doxylamine (moderate symptoms) are associated with improved nausea and 
vomiting in pregnancy as compared to placebo. Ondansetron is associated with symptom 
improvement for all severity of nausea and vomiting in pregnancy and hyperemesis 
gravidarum, and corticosteroids were associated with beneficial effects in severe cases.  
Meaning: Both over-the-counter and prescription therapies are associated with improved 
symptoms of nausea and vomiting in pregnancy and hyperemesis gravidarum, although the 
evidence supporting these therapies is generally of low quality.  
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Treatments for Hyperemesis Gravidarum and Nausea and Vomiting in Pregnancy: 
A Systematic Review  
ABSTRACT 
Importance: Nausea and vomiting affects approximately 85% of pregnant women. The most 
severe form, hyperemesis gravidarum– affects up to 3% of women and can have significant 
adverse  physical and psychological sequelae.  
Objective: To summarize current evidence on effective treatments for nausea and vomiting 
in pregnancy and hyperemesis gravidarum. 
Evidence Review: Databases were searched to 8th June 2016.  Relevant websites and 
bibliographies were also searched.  Results were narratively synthesised; planned meta-
analysis was not possible due to heterogeneity and incomplete reporting of findings. 
Findings: 78 studies were included; 67  randomized clinical trials s and 11 non-randomized 
studies.  
Evidence from 35 randomized clinical trial s at low risk of bias indicated that ginger, vitamin 
B6, antihistamines, metoclopramide (mild symptoms), pyridoxine-doxylamine and 
ondansetron (moderate symptoms) were associated with improved symptoms as compared to 
placebo. One randomized clinical trial , (n=86), reported greater improvements in moderate 
symptoms following psychotherapy, change in Rhodes score (range 0=no symptoms to 
40=worst possible symptoms) intervention: 18.76(5.48) to 7.06(5.79) versus comparator: 
19.18(5.63) to 12.81(6.88) (p<0.001). For moderate-severe symptoms one randomized clinical trial 
(n=60) suggested that pyridoxine-doxylamine combination taken pre-emptively reduced risk 
of recurrence of moderate-severe symptoms (15.4%) compared to treatment once symptoms 
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begin (39.13%) (p<0.04). One  randomized clinical trial, (n=83), found that ondansetron was 
associated with lower nausea scores on day 4, (using a VAS where 0=no symptoms to 
10=worst possible symptoms) than metoclopramide (mean (SD) nausea ondansetron: 4.1(2.9) 
versus metoclopramide: 5.7(2.3)(p=0.023), but not episodes of emesis 5.0(3.1) versus 3.3(3), 
respectively(p = 0.013)). However there was no difference in trend in nausea scores over the 
14 day study period but trend in vomiting scores was better in the ondansetron group 
(p=0.042). Another  randomized clinical trial (n=159), found no difference between 
metoclopramide and promethazine after 24 hours, [(episodes of vomiting: 1(0–5) versus 2(0–
3)(p=0.81), VAS (0-10) for nausea: 2 (1–5) versus 2 (1–4) (p=0.99)]. Three randomized 
clinical trial s compared corticosteroids with placebo or promethazine or  metoclopramide in 
women with severe symptoms. Improvements were seen in all corticosteroid groups but only 
a significant difference between corticosteroids and metoclopramide was reported (emesis 
reduction: corticosteroid group days 2, 3 and 7= 40.9%, 71.6%, 95.8% versus 16.5%, 51.2%, 
76.6% (n=40, p<0.001)).  For other interventions, evidence was sparse.   
 
Conclusions and Relevance:  
For mild symptoms of nausea and emesis of pregnancy, ginger, pyridoxine, antihistamines 
and metoclopramide were associated with greater benefit than placebo. For moderate 
symptoms, pyridoxine-doxylamine, promethazine and metoclopramide were associated with 
greater benefit than placebo. Ondansetron was associated with improvement  for a range of 
symptom severity.  Corticosteroids may be  associated with benefit in severe cases. .Overall 
the quality of evidence was low. 
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INTRODUCTION  
Nausea and vomiting in pregnancy is a common but debilitating condition affecting up to 
85% of women1. The most severe form, hyperemesis gravidarum, affects 0.3 to 3% of 
pregnant women and is characterized by intractable vomiting, dehydration, electrolyte 
imbalance, ketosis, nutritional deficiencies and weight loss 2. Symptoms usually start by six 
to eight weeks gestation and subside before 20 weeks1. In severe cases, women may require 
prolonged hospitalization and support from enteral or parenteral nutrition.  
Symptoms can affect  day-to-day functioning3, ability to work4, and interactions with 
offspring, family and friends5. A recent systematic review and meta-analysis reported an 
association between hyperemesis gravidarum pre-term delivery and small-for- gestational age 
infants, although there was no association with congenital anomalies or perinatal death6.  
 
This article reviews evidence regarding treatments for varying severity of symptoms of 
nausea and vomiting in pregnancy or hyperemesis gravidarum.  
METHODS  
We searched electronic databases (MEDLINE, EMBASE, CENTRAL, CDSR, DARE, 
CINAHL, British Nursing Index, PsycINFO, CAB Abstracts, LILACS, AMED, Science 
Citation Index, Social Science Citation Index, Scopus, Conference Proceedings Index – 
Science, Clinicaltrials.gov, NHS-EED, HEED, China National Knowledge Infrastructure) 
and key websites for randomized clinical trials  and non-randomized comparative studies of 
pharmacological or non-pharmacological intervention for nausea and vomiting in pregnancy 
or hyperemesis gravidarum, without language restriction, from inception to 8th June  2016, 
using terms describing: (1) nausea, vomiting or hyperemesis gravidarum; (2) pregnancy (see 
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eBox 1). We also searched for population-based case series, for estimates of rare adverse 
events and fetal outcomes, and for treatments reserved for the most severe cases of 
hyperemesis gravidarum. 
Titles and abstracts were assessed independently by two reviewers (AO, CMP). The full text 
of each relevant article was reviewed to further determine eligibility. Major exclusion criteria 
were: studies with participants recruited after 20 weeks gestation; no relevant outcomes 
reported (either via a validated scale or author-defined scale, see Table 1).  Discrepancies 
were resolved by consultation with another reviewer (AB). Full text articles published in 
languages other than English were assessed by research trained native speakers working 
alongside the reviewers to ensure consistency.  
An electronic data form was used to  compile abstracted information.  Methodological quality 
was assessed using the Cochrane Collaboration's Risk of Bias tool7 for randomized clinical trial 
s and the Effective Public Health Practice Project (EPHPP) tool8 for non-randomized studies. 
An evidence grade (A-C) and recommendation (I-III) was assigned using the American Heart 
Association (AHA) scale for each treatment (see eBox 2)9.  
Both fixed- or random- effect model meta-analysis and a Bayesian mixed treatment 
comparison were planned, but were not performed due to heterogeneity in interventions, trial 
populations, reporting and definitions of outcome measures and methods. Data were therefore 
summarized narratively, and prioritized to emphasize the highest quality of evidence, defined 
as randomized clinical trial s with a low risk of bias.   
RESULTS 
13,075 titles were identified, of which 222 underwent full review. Seventy-eight studies met 
our inclusion criteria (see eFigure 1). Of these, 11 randomized clinical trial s were classified as 
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having high within-study risk of bias, mainly due to allocation concealment bias, lack of 
blinding, incomplete outcome data or selective outcome reporting. Twenty one were 
classified as being at unclear risk of bias, mainly due to poor reporting and lack of 
methodological detail. The quality of case series and non-randomised studies was weak (n=9) 
or moderate (n=2)8. The remaining 35 randomized clinical trial s were at low risk of bias, and 
are presented below and summarised in Table 2a,b,c (see eTables 1-3 for details of all other 
included studies).   
Treatment  
Treatment focuses on relieving symptoms and preventing serious morbidity such as 
Wernicke's encephalopathy, renal impairment and extreme weight loss.10-12. Treatments can 
be categorized in three broad yet overlapping groups. First-line treatments, including simple 
lifestyle changes, (such as eating small amounts often,  avoiding dietary triggers and strong 
odours, eating high carbohydrate, low fat foods) and over-the-counter remedies, such as 
vitamin B6 (pyridoxine), ginger and sea bands ( an acupressure towelling wrist band which 
stimulates the Pericardium P6 acupressure point), and are usually initiated by women when 
first experiencing symptoms. Second-line treatments are typically prescribed when a 
woman first presents to medical care, usually by her obstetric care provider, and include a 
range of anti-emetic drugs as well as provision of intravenous fluid and electrolyte 
replacement for women who are dehydrated and ketotic. Third-line treatments are reserved 
for women with severe, persistent symptoms and are initiated in a hospital setting. These 
include corticosteroids and supportive therapy, such as enteral feeding. Depending on 
symptom severity, women may progress from one category to another or may bypass first-
line treatments. When second or third-line treatments fail, some women opt for termination of 
pregnancy13,14. An international on–line survey carried out by the Hyperemesis Education and 
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Research Foundation reported that of 808 respondants, 15.2% stated that they  underwent at 
least one pregnancy termination for hyperemesis gravidarum13.   
First-line treatments for mild to moderate symptoms 
Ginger 
Ginger (Zingiber officinale) is available in several preparations: powdered fresh root; tablets; 
capsules; and syrup. Its anti-nausea properties were first described in traditional Chinese 
medicine15. Four randomized clinical trial s compared ginger with placebo, and all reported an 
improvement in symptoms from baseline compared with placebo, regardless of the ginger 
dose and preparation16-19. Basirat et al  (n=70) reported greater improvement in symptoms on 
a visual analogue scale (VAS, participants specify their level of symptom severity by 
indicating a position along a continuous line between zero (no symptoms) and ten (worst 
possible symptoms, see Table 1). The ginger group changed from a mean (SD) 5.88 (1.83) at 
baseline to 3.03 (2.19) on day 4 compared to from 4.67 (1.97) to 3.03 (2.47) for the placebo 
group (p=0.01) but there was no difference in episodes of vomiting. Fischer-Rasmussen et 
al17 (n=30) reported that mean nausea and vomiting relief score, (a complex score designed 
by the authors which takes into account intensity of nausea, vomiting, weight loss, Ketonuria 
and haematocrit, range not provided), improved more for ginger (ginger improvement 4.1 and 
3.7 for two, five day treatment periods compared to -0.1 and 0.9 for placebo p=0.035). 
Vutyavanich et al (n=70) reported a greater improvement in VAS for nausea (2.1 v 0.9, 
p=0.014) and vomiting episodes (1.4 v 0, p<0.001) in the ginger group compared to placebo; 
similarly Keating et al (n=26) reported greater improvements in a VAS for nausea (10 women 
in the ginger group had greater than a  4-point improvement compared to 2 in the placebo 
group by day 9), and a greater proportion stopped vomiting in the ginger group (8 women in 
the ginger group compared to 2 in the placebo group by day 6, p value not reported). 
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Four randomized clinical trial s compared ginger capsules and vitamin B6. Chittumma et al 
(n=126) and Ensiyeh et al (n=70) reported greater improvements in nausea scores in women 
taking ginger capsules compared with vitamin B6 (Chittumma: improvement in Rhodes score 
3.3 v 2.5, p<0.05; Ensiyeh: change in VAS 2.2 v 0.9, p=0.024) 20,21. Smith et al (n=291) and 
Sripramote et al (n=138) found no differences between the efficacy of ginger and vitamin B6. 
Sripramote reported improvements in symptoms within each group via VAS for nausea and 
episodes of vomiting, but no difference between groups 22,23. Similarly Biswas et al, (n=78), 
compared ginger with a doxylamine-pyridoxine combination24 and reported symptom 
improvement within each group via VAS, but no difference between groups. Compared with 
sea-bands, Saberi et al, (n=159), reported that ginger capsules were associated with a greater 
improvement in symptoms (Rhodes score improvement ginger 8.61, sea-bands 4.17. 
p<0.001)25.  
In summary, treatment with ginger is associated with improvement in mild symptoms (Level 
A Class IIa).  . 
Acupressure, acupuncture and nerve stimulation 
Acupressure involves the application of physical pressure to specific acupuncture points (the 
Pericardium 6 [P6] point lies one sixth of the distance up the arm from the inner aspect of the 
wrist between the two tendons. Pressure at this point is believed to reduced symptoms of 
nausea and vomiting). Three randomized clinical trial s compared acupressure with placebo in 
women with mild symptoms. Bayreuther et al (n=23) and Belluominin et al (n=60)26,27 
reported improved symptoms from baseline following acupressure at P6 compared to 
pressure an alternative location (Bayreuther:  improvement in VAS for nausea in the 
treatment group 3.23, placebo 4.92 (p=0.019); Belluomini reported improvement in 
symptoms in both groups but only a significant improvement for vomiting in the acupressure  
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group (change in Rhodes score from 2.09(2.5) to 1.28(1.9), p=0.03 verses 1.83(2.7) to 
1.63(2.3), p not reported in the placebo group). Naemi-Rad et al (n=80) reported reduced 
symptoms of nausea and vomiting after two days when comparing acupressure at acupoint 
Kidney 21(KID21,  a traditional Chinese point on the upper abdomen, 6cm above the 
umbilicus, 5am lateral to the anterior midline) to non-stimulation28 (median (IQR) VAS for 
nausea intensity acupoint group: 4 (2-5), comparator 7 (5-8) (p<0.001) and vomiting 0 (0-
0.75) v 1 (0=2) (p<0.001)).   
Rosen et al (n=230) compared nerve stimulation with placebo and reported a greater 
improvement in the Rhodes score in the treatment group, (mean change from baseline 6.48 
(95% CI 5.31, 7.66) v 4.65 (95% CI 3.67, 5.63) (p=0.02)) 29. 
Jamigorn and Phupong (n=66) compared five days treatment with acupressure, using sea-
bands plus placebo tablet to treatment with bands at non-stimulating position plus vitamin B6 
50mg twice daily 30. Both were allowed to take Dimenhydrinate 50mg every six hours as 
needed. Symptoms improved in each group with no difference in improvement between 
groups.  Use of  dimenhydrinate was not different between the groups.  
Three randomized clinical trial s compared acupuncture with other treatments. A four-group 
randomized clinical trial  conducted by Smith et al (n=593) compared traditional acupuncture, 
P6 acupuncture, sham treatment versus. an information brochure. Women receiving 
traditional and P6 acupuncture had less nausea by the third week compared with women in 
the sham treatment and information only group (Rhodes Index nausea component score 
[range 0-12, 0=best]: traditional =3.8; P6 =4.3; sham =4.4; control =5.8 (p=0.001))31. No 
differences in vomiting scores were found between the groups over the three week study 
period.  A crossover trial by Carlsson et al (n=33) reported a reduction in symptoms over 
time but no difference between P6 and sham accupuncture in nausea symptoms after a six 
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day treatment period32. A similar outcome was found by Knight et al, (n=56), (final VAS  
score [range 0, no symptoms-100, worst possible symptoms] for nausea [median IQR] 3 days 
after session 4; P6=47.5 (29.25-69.5) v sham=48.0 (14.0–80.0))33.  
In summary for acupressure: treatment with acupressure wass associated with symptom 
improvement for mild cases (Level A Class IIa). 
For nerve stimulation: evidence indicates treatment may be considered but the benefit was 
unclear (Level B Class IIb).  
For acupuncture:  the  benefit is unclear (Level A Class IIb). 
Vitamin B6 (pyridoxine) 
Two randomized clinical trial s examined the association of vitamin B6 with improvement in 
people with mild to moderate symptoms. Vutyavanich et al34 (n=342) compared vitamin B6 
(one mg three times daily) with placebo. Vitamin B6 was associated with a greater reduction 
in nausea VAS score from baseline compared with a placebo tablet (2.9(2.2) v 2.0(2.7) 
[p<0.001]). There was no difference in reported vomiting34. When high and low dose vitamin 
B6 (10 mg versus 1.28 mg daily) were compared in 60 women, a greater change in PUQE 
score (three question scale, scoring from 0=no symptoms to 15=worst possible symptoms, 
see Table 1) was reported in the high dose group (high dose=3.86(2.12), low dose=2.80(1.78) 
(p<0.05))35. 
In summary, treatment with vitamin B6 is associated with symptom improvement for mild 
cases (Level A Class IIa. 
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Second-line treatments for moderate-severe symptoms 
Vitamin B6 (pyridoxine)/doxylamine combination 
Three randomized clinical trial s compared pyridoxine-doxylamine combinations with either 
placebo or ondansetron. Koren et al (n=280) compared pyridoxine 10mg plus doxylamine 
10mg, slow release preparation, with placebo over 14 days 36. Symptoms improved in both 
groups, but the improvement in the pyridoxine-doxylamine group was greater (mean change 
in PUQE score 4.8 v 3.9, p= 0.006).  
Oliveira et al (n=36) compared pyridoxine-doxylamine with ondansetron 37. Symptom 
improvement occurred in both groups but was greater in the ondansetron group (median 
(IQR) change using a 0-100VAS for nausea: ondansetron=51(37-64), pyridoxine-
doxylamine= 20 (8-51) (p=0.019) and vomiting ondansetron=41 (17-57), pyridoxine-
doxylamine=17 (4-38), p=0.049). Maltepe et al (n=60) compared pre-emptive treatment with 
pyridoxine-doxylamine to treatment once symptoms started 38. Moderate-severe symptoms 
were reduced in the pre-emptive group, 15.4%, compared to the post-symptom group, 39.1% 
(p<0.04).  
In summary, treatment with vitamin B6 (pyridoxine)-doxylamine is associated with symptom 
improvement for women with mild-moderate symptoms (Level A Class IIa). 
Erez et al (n=150) compared hydroxyzine hydrochloride (25 mg twice daily for three weeks) 
with placebo39. Symptom improvement occurred in the treatment group with partial or 
complete relief of symptoms in 82% of women, compared to only 22% in the placebo group 
(p<0.01).  
In summary, limited quality evidence indicates that treatment with antihistamines is 
associated with symptoms improvements in mild-moderate cases (Level B Class IIa). 
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Psychotherapy 
A randomized clinical trial by Faramarzi et al (n=86) compared psychotherapy treatment with 
standard care 40. All women received 40mg of vitamin B6 daily and  the treatment group 
received eight 50 minute psychotherapy sessions over a three week period. A greater change 
in the mean Rhodes score was seen in the treatment group, (18.76 to 7.06 versus 19.18 
to12.81, p<0.001). 
In summary for psychotherapy: limited evidence indicates that psychotherapy plus vitamin 
B6 is associated with greater benefit than vitamin B6 alone (Level B Class IIa,). 
Dopamine antagonists 
Tan et al  (n=159) compared metoclopramide 10mg to promethazine 25mg given 
intravenously (IV) three times over 24 hours 41. Symptoms improved in both treatment 
groups, with no difference between groups.  
In summary, evidence indicated that treatment with dopamine receptor antagonists was 
associated  with  improved symptoms (Level A Class IIa). 
Serotonin antagonists (ondansetron) 
Two randomized clinical trial s compared ondansetron with metoclopramide. Abas et al (n=160) 
compared ondansetron 4mg IV with metoclopramide 10mg IV42. Symptom improvement was 
seen in both groups with no evidence of difference between groups at 24 hours. However, 
more women in the metoclopramide group reported side effects (drowsiness: ondansetron 
12.5% v metoclopramide 30% (p=0.011), and dry mouth: ondasetron 10% v metoclopramide 
23.8% (p=0.03). Kashifard et al (n=83) compared ondansetron  with metoclopramide over 
two weeks.43.  The ondansetron group had lower vomiting scores than the metoclopramide 
group calculated over 14-days (p=0.042, raw data not provided) but there was no difference 
in trend in nausea scores over 14 days between groups . 
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In summary, treatment with serotonin receptor antagonists was associated with improvement 
in symptoms of all severities (Level A Class IIa). 
Intravenous fluids 
Tan et al (n=222) compared different compositions of IV solution 44. The intervention group 
received IV dextrose saline with anti-emetics according to healthcare provider preference, 
while the comparator group received normal saline with antiemetics. Repeated measures 
analysis of variance of nausea score found greater improvements in the dextrose saline group 
relative to the saline group (p=0.046) but no difference in vomiting was reported.  
In summary, limited evidence indicates that dextrose saline may be associated with better 
improvements than normal saline in moderate-severe cases (Level B Class IIa). 
Outpatient/day-case management 
Two randomized clinical trial s compared day-care outpatient management with inpatient care. 
McParlin et al (n=53) reported no difference in symptom severity over seven days between 
women who received outpatient rehydration and anti-emetics (Cyclizine 50mg IV/oral) 
versus inpatient care45. McCarthy et al (n= 98) also compared outpatient with inpatient care46. 
The median (IQR) number of nights spent in hospital was lower in the outpatient group (0 [0-
2] versus 2 [1-4] nights, p<0.001).  
In summary, evidence indicates that outpatient treatment was asscoiated with benefits that are 
not better or worse than    in-patient intravenous therapy in patients with moderate symptoms 
(Level A Class IIa).   
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Third-line treatments for moderate-severe symptoms 
Corticosteroids 
Three randomized clinical trial s compared corticosteroids with placebo or other treatments. 
Nelson-Piercy et al (n=40) compared prednisolone  with placebo 47. There was no difference 
in vomiting and nausea scores in the steroid group compared with placebo. Safari et al (n=40) 
compared methylprednisolone  with promethazine 48. There was no difference in symptom 
improvement by one week. However, no patients from the methylprednisolone group were 
readmitted for recurrence of vomiting compared to five patients from the promethazine group 
(p<0.01).   
Bondok et al (n=40) compared hydrocortisone with metoclopramide 49. Steroids were 
associated with a greater reduction in vomiting episodes compared with metoclopramide 
(96% reduction in the steroid group v 77% in the metoclopramide group on day seven, 
p<0.001). 
In summary, evidence indicated  that benefits  of corticosteroids were unclear.  , Treatment 
may be considered in severe cases (Level A Class IIb) 
Transdermal clonidine 
Transdermal clonidine patches were investigated in one randomized cross-over trial by Maina 
et al (n=12) in patients unresponsive to other anti-emetics50. Either clonidine or placebo 
patches were worn for five days before the treatment was alternated. IV fluids and rescue 
anti-emetics were given as required. The mean improvement in symptom scores was greater 
for clonidine treatment (mean PUQE score: clonidine=6.3(5.5-7.1), placebo= 8.5(7.7-9.3), 
p=0.001), and there was less use of anti-emetics and IV therapy in the clonidine group.  
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In summary, limited evidence indicates treatment with transdermal clonidine is associated 
with symptom improvements but currently this is not an established treatment (Level B Class 
IIb.  
DISCUSSION 
The review found low quality evidence for therapies treating nausea and vomiting in 
pregnancy and hyperemesis gravidarum. Less than half of all studies were judged as being at 
low risk of bias.  
Ginger, acupressure and vitamin B6 are appropriate initial ‘over the counter’ (OTC) therapies 
for mild symptoms, treatment with nerve stimulation may be considered but, as with 
acupuncture, the benefit is unclear.  
When symptoms are mild-moderate, or if the above OTC therapies were not beneficial, 
antihistamines (alone or combined with vitamin B6) were associated with improved 
symptoms compared with placebo. Limited evidence indicates an association between 
psychotherapy, metoclopramide and promethazine and improvements in moderate symptoms. 
There is no evidence to indicate that these treatments are unsafe, but more research is needed.  
When symptoms are moderate- severe, outpatient, day-care management is feasible, 
acceptable and does not result in worse outcomes compared to inpatient care. The serotonin 
receptor antagonist, ondansetron, improves symptoms at all severities but benefit compared 
to metoclopramide or antihistamines is unclear. Ondansetron appears to be safe in pregnancy 
51 but evidence is limited and more research is needed. Large doses of IV ondansetron (more 
than 8mg in one intravenous dose) are contraindicated in women at risk of cardiac 
arrhythmias (QT prolongation). In such circumstances an ECG should be performed and 
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electrolytes checked prior to treatment52. There is no evidence that oral administration of 
ondansetron causes QT prolongation in adults59. 
When symptoms are more severe or persistent, corticosteroids are associated with 
improved  symptom severity and may be more beneficial than metoclopramide and 
promethazine. However, use is generally limited to women with severe intractable symptoms 
with prior treatment failure(s), preferably after 10 weeks gestation and during an inpatient 
admission. This arises from concerns regarding a small increase in oral clefts in fetuses 
exposed to corticosteroids in utero in pooled data from observational studies53. More 
evidence is needed comparing corticosteroids to other medications. 
Comparison with previous literature 
The American College of Obstetricians and Gynaecologists published clinical management 
guidelines in August 20152, recommending the use of vitamin B6 or Vitamin B6 plus 
doxylamine as first line pharmacotherapy, ginger as a non-pharmacological option and 
methylprednisolone in refractory cases. Recommendations based on consensus include 
intravenous hydration and enteral tube feeding for women who are not responsive to medical 
therapy. Many of the findings in this review support recommendations in the guidelines. 
However although pyridoxine plus doxylamine is more effective than placebo, there is no 
substantial evidence to suggest that the combination is more effective than other antiemetics 
such as antihistamines. Moreover, this review adds value by categorizing therapies depending 
on symptom severity. Two Cochrane reviews  were published recently54 55. Matthews et al54 
only focused on nausea and vomiting and randomized clinical trial’s, excluded trials involving 
hyperemesis gravidarum, Boelig et al55 only included randomized clinical trial’s  of 
hyperemesis gravidarum. Neither review categorized therapies depending on symptom 
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severity. However, both reviews  are consistent in concluding that there is little good quality 
evidence to support any available intervention. 
Limitations 
These recommendations are limited by the quality and heterogeneity of evidence. Quality 
was downgraded due to clinical heterogeneity, imprecision, a sparseness of data or a 
combination of these factors. There was also considerable variation in the initial assessment 
and subsequent reporting of nausea, vomiting and other relevant outcomes in the identified 
studies. As a result, we were unable to conduct the planned meta-analysis stipulated in our 
original protocol (PROSPERO CRD42013006642).   
One set of outcome measures that is likely to be very important to women and practitioners is 
safety. We sought to assemble data on fetal outcomes and adverse events, however no 
reliable safety data were identified in the included studies. Details of common side effects of 
the interventions recommended by this review are provided in Table 4 along with common 
dosage regimes. Available observational data (pregnancy-related but not specifically focused 
on nausea and vomiting) does not provide evidence of any safety concerns with anti-emetic 
medications, this is not the same as ruling out any important differences in adverse outcomes.   
CONCLUSION 
For mild symptoms, ginger, pyridoxine, antihistamines and metoclopramide are associated 
with greater benefit than placebo. For moderate symptoms, pyridoxine-doxylamine, 
promethazine and metoclopramide are associated with greater benefit than placebo. 
Ondansetron is associated with symptom improvement at all severity levels and 
corticosteroids may be beneficial in severe cases. The quality of evidence for other 
interventions is low.  
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Table 1: Tools used to measure the severity of nausea and vomiting in pregnancy 
Tool Description Scoring Maximum 
score 
Cut point for severe 
symptoms 
Pregnancy 
Unique 
Quantification 
of Emesis and 
Nausea (PUQE 
and PUQE 24 
score ) 56-58 
Three questions 
regarding nausea, 
vomiting and retching 
during previous 12 
hours (original 
version), or 24 hours 
(most commonly used 
version). 
For each 
question: 0 = no 
symptoms; 5 = 
worst possible 
symptoms.  
 
15 Scores ≥ 13 indicate 
severe symptoms 
The Rhodes 
Index of Nausea, 
Vomiting and 
Retching 
(RINVR) 59-61  
Eight questions about 
duration/amount, 
frequency and distress 
caused by symptoms 
of nausea, vomiting 
and retching 
 
For each 
question: 0 = no 
symptoms, 5 = 
worst possible 
symptoms.  
 
40  Scores ≥ 33 indicated 
severe symptoms 
Nausea and 
vomiting of 
pregnancy 
Instrument 
(NVPI) 62,63 
Three questions 
relating to nausea, 
retching and vomiting 
over the past 7 days.  
 
For each 
component: 0 = 
no symptoms, 5 = 
worst possible 
symptoms. 
 
15 Score ≥ 8 indicates 
severe symptoms 
Visual analogue 
scale (VAS) 
Patients rate their 
symptoms on a scale 
of 0-10.  
Visual analogue 
scale: 0 = no 
symptoms; 10 = 
extreme 
symptoms. 
10 Not applicable 
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Table 2a: Summary of findings from trials at low risk of bias evaluating the effectiveness of firs-line interventions for nausea and 
vomiting and hyperemesis gravidarum in pregnancy 
Study details Participants and treatments Outcome measures and results 
Author, 
year 
(country) 
Study 
Design 
Baseline 
symptom 
severity1 
Number of 
participants  
Gestation 
in weeks 
Mean 
(range) 
Dosage and 
duration 
Primary 
Outcome 
Measures 
Results  
 
p value 
FIRST-LINE INTERVENTIONS 
Ginger versus placebo (4 Randomized Clinical Trials ) 
Fischer-
Rasmusse
n et al., 
199017 
(Denmark) 
Double 
blind 
randomi
zed 
crossov
er trial 
Mild-
moderate 
Intervention=15 
 
11 (7-17)  
 
Ginger capsules 
(250mg powdered 
root ginger, 4 x 
daily for 4 days 
then 2 day 
washout) 
 
Nausea severity 
change score 
 
Intervention = 13.7 1st 
5 days 8.2 2nd 5 days.  
Comparator = 13.3 1st 
5 days 8.9 2nd 5 days. 
  
p=not 
significantly 
different 
 
Comparator=15 10.8 (7-16) Placebo capsules 
(250mg lactose, 4 x 
daily for 4 days 
then 2 day 
washout). 
Nausea and 
vomiting relief 
change score 
Intervention = 4.1 1st 5 
days and 3.7 2nd 5 
days 
Comparator = -0.1 1st 
5 days and 0.9 2nd 5 
days 
p=0.035 
Vutyavani
ch et al., 
200118 
(Thailand) 
Double 
blind 
Rando
mized 
Clinical 
Trial 
Mild Intervention=32 
 
10.4 (2.3) 
 
 
 
 
 
Ginger capsules 
(250mg ginger 3 
times daily 
following meals and 
another before bed 
for 4 days) 
 
Decrease in 
Visual Analogue 
Scale for nausea 
 
Intervention = 2.1(1.9)  
Comparator = 0.9(2.2)  
p=0.014.  
 
                                                 
1 Symptom severity was classified by two independent assessors (CMP and SCR) as either mild, moderate or severe, based on the description of severity reported in the study inclusion criteria and, 
if available, any severity score provided at baseline. 
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Study details Participants and treatments Outcome measures and results 
Author, 
year 
(country) 
Study 
Design 
Baseline 
symptom 
severity1 
Number of 
participants  
Gestation 
in weeks 
Mean 
(range) 
Dosage and 
duration 
Primary 
Outcome 
Measures 
Results  
 
p value 
Comparator=38 10.3 (2.6) Placebo capsules 
(3 times daily 
following meals and 
another before bed 
for 4 days). 
Decrease in 
episodes of 
vomiting 
Intervention = 1.4(1.3)  
Comparator = 0.(±1.1)  
p <0.001 
Keating & 
Chez, 
200219 
(USA) 
Double 
blind 
Rando
mized 
Clinical 
Trial 
Mild Intervention=14 
 
Range 7-
11 
I250mg ginger + 
honey and water, 4 
x daily for 2 weeks)  
Visual Analogue 
Scale for nausea 
by day 9 
 
Intervention=10 
women  ≥ 4-point 
improvement 
Comparator = 2 
women≥ 4-point 
improvement  
 
Not reported 
Comparator=12   Placebo syrup of 
water, honey and 
lemon oil, 4 x daily 
for 2 weeks). 
Vomiting stopped 
by day 6 
Intervention=8 women 
Comparator=2 women 
Basirat et 
al., 200916 
(Iran) 
Double 
blind 
Rando
mized 
Clinical 
Trial 
Mild Intervention=35 
 
Range 7-
17 
Ginger biscuits 
(0.5mg ginger, 5 x 
daily for 4 days 
 
Visual Analogue 
Scale for nausea 
 
Average change: 
Intervention 
=2.57(1.77)  
Comparator 
=1.39(1.62)  
p=0.01 
Comparator=35 Non-ginger biscuits 
(5 x daily for 4 
days). 
Episodes of 
vomiting 
Average change:   
Intervention = 
0.96(0.2)  
Comparator = 
0.62(0.19)  
p=0.243 
Ginger versus vitamin B6 (4 Randomized Clinical Trials ) 
Sripramot
e & 
Lekhyana
Double 
blind 
Rando
mized 
Mild-
moderate 
Intervention=68 
 
10.1 (2.74) 
 
Ginger capsules 
(500mg, 3 x daily 
for 3 days)  
 
Mean change in 
Visual Analogue 
Scale 
 
Intervention = 
5.0(1.99) to 3.6(2.48)  
Comparator = 
5.3(2.08) to 3.3(2.07)  
p<0.001 
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Study details Participants and treatments Outcome measures and results 
Author, 
year 
(country) 
Study 
Design 
Baseline 
symptom 
severity1 
Number of 
participants  
Gestation 
in weeks 
Mean 
(range) 
Dosage and 
duration 
Primary 
Outcome 
Measures 
Results  
 
p value 
nda, 
200323 
(Thailand) 
Clinical 
Trial 
Comparator=70 10.3(2.95) Vitamin B6 
capsules (10mg, 3 
x daily for 3 days). 
Episodes of 
vomiting 
Intervention = 
1.9(2.06) to 1.2(1.75)  
Comparator = 
1.7(1.81) to 1.2(1.50)  
p<0.01 
Smith et 
al., 200422 
(Australia) 
Rando
mized, 
controll
ed 
equival
ence 
trial. 
Mild-
moderate 
Intervention=14
6 
 
Median 
(IQR) 
8.5 (8-15) 
 
Ginger capsules 
(350mg, 3 x daily 
for 3 weeks) 
 
Mean difference 
(Confidence 
Intervals) in 
Rhodes Index 
score: 
Nausea 
 
 
 
 
0.2, (90% CI -0.3, 0.8)  
p values not 
reported 
Comparator=14
5   
8.6 (8-15) Vitamin B6 
capsules (25mg, 3 
x daily for 3 weeks). 
Vomiting 
 
0.3 (90% CI -0.0, 0.6)  
Retching 0.5 (90% CI 0.0, 0.9)  
Chittumma 
et al., 
200720 
(Thailand) 
Double 
blind 
Rando
mized 
Clinical 
Trial 
Mild Intervention=63 
 
12 (2) 
 
Ginger capsules 
(2x 325mg 4 times 
daily for 4 days) 
 
Mean change in 
combined 
Rhodes Index 
score 
Intervention = 3.3(1.5)   
Comparator = 2.6(1.3)  
p < 0.05 
Comparator=63 11 (2) Vitamin B6 
capsules (2x 
12.5mg 4 times 
daily for 4 days). 
Ensiyeh & 
Sakineh, 
200921 
(Iran) 
Double 
blind 
Rando
mized 
Clinical 
Trial 
Mild Intervention=35  
 
Not 
reported 
Ginger capsules 
(500mg 2 x daily for 
4 days) 
 
Mean change in 
VAS 
 
Intervention = 2.2(1.9)   
Comparator = 0.9(1.7)  
 
p=0.024 
Comparator=35 Vitamin B6 
capsules (20mg 2 x 
daily for 4 days). 
Episodes of 
vomiting 
Intervention = 0.6(0.7)  
Comparator = 0.5(1.1)  
p=1.1012 
                                                 
2 P value as reported in paper. 
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Study details Participants and treatments Outcome measures and results 
Author, 
year 
(country) 
Study 
Design 
Baseline 
symptom 
severity1 
Number of 
participants  
Gestation 
in weeks 
Mean 
(range) 
Dosage and 
duration 
Primary 
Outcome 
Measures 
Results  
 
p value 
Ginger versus acupressure (1 Randomized Clinical Trial) 
Saberi et 
al., 
201325 
(Iran) 
Three-
group 
Rando
mized 
Clinical 
Trial 
Mild-
moderate 
Intervention=53 
 
8.78(2.32) 
 
Ginger capsules 
(250mg, 3 x daily 
for 4 days) 
 
Mean difference 
in combined 
Rhodes Index 
score 
Intervention = 
8.61(5.24)   
Comparator = 
4.17(5.53)  
Control = 0.84(3.72)  
p<0.001 
Comparator=53 
 
9.32( 2.38) 
 
Acupressure (sea 
bands worn 
continuously for 4 
days) 
 
Control=53   9.11(0.18) No intervention. 
Ginger versus vitamin B6 / doxylamine combination (1 Randomized Clinical Trial) 
Biswas et 
al., 
201124 
(India) 
Single 
blind 
Rando
mized 
Clinical 
Trial 
Mild Intervention=42 
 
10.25(2.8) 
 
Ginger tablets 
(150mg, 3 x daily 
for one week) 
 
Median Visual 
Analogue Scale 
for nausea 
 
Intervention = 3 to 
0.43   
Comparator = 4 to 0.6   
 
p value not 
reported 
Comparator=36 9.3(3.1) Doxylamine 10mg 
plus pyridoxine 
10mg, (3 x daily for 
one week). 
Mean Visual 
Analogue Scale 
for vomiting 
Intervention = 1 to 
0.14 
Comparator = 2 to 0  
Acupressure versus placebo (3 Randomized Clinical Trials ) 
Bayreuthe
r et al., 
199426 
(UK) 
Rando
mized 
Clinical 
Trial 
Mild Intervention=11 
 
≤16 Sea-bands at P6 
point (7 
consecutive days 
then 2 days no 
treatment) 
 
Treatment 
difference in 
mean Visual 
Analogue Scale 
Paired t-test=1.69 
Two sample t-
test=1.67 
Wilcoxon=1.65 
Mann Whitney U=1.61  
p not 
reported 
Comparator=12 Sea-bands at 
placebo position (7 
consecutive days 
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Study details Participants and treatments Outcome measures and results 
Author, 
year 
(country) 
Study 
Design 
Baseline 
symptom 
severity1 
Number of 
participants  
Gestation 
in weeks 
Mean 
(range) 
Dosage and 
duration 
Primary 
Outcome 
Measures 
Results  
 
p value 
followed by 2 days 
no treatment). 
Belluomini 
et al., 
199427 
(USA) 
Rando
mized 
Clinical 
Trial 
Mild Intervention=30 
 
8.5(1.4) 
 
3 days no treatment 
then self-
administered 
acupressure (10 
minutes, 4 x daily 
for 7 days at point 
PC-6)  
 
Change in 
Rhodes index for: 
 
Nausea 
 
 
 
 
Intervention = 
5.80(2.9)  
Comparator = 
7.04(2.6)  
 
 
 
 
p≤ 0.001  
p≤ 0.001  
 
Comparator=30 8.6(1.4) 3 days no treatment 
followed by self-
administered 
acupressure (10 
minutes, 4 x daily 
for 7 days at 
placebo point). 
Vomiting 
 
Intervention = 
1.28(1.9)  
Comparator= 1.63(2.3)  
 
p=0.03 
p=not 
reported 
Combined Intervention = 
8.69(5.0)  
Comparator = 
10.03(4.6)  
p≤0.001 
p=0.019 
Naeimi 
Rad et al., 
201228 
(Iran) 
Rando
mized 
Clinical 
Trial 
Mild-
moderate 
Intervention=40 
 
9.55(1.81) 
 
Acupressure to 
KID21 points (20 
minutes daily for 4 
days + during 
nausea and 
vomiting episodes) 
 
Median Visual 
Analogue Scale 
(IQR) at day 4 
day for: 
Intensity of 
nausea 
 
 
 
 
 
Intervention = 4(5-2)  
Comparator =7 (8-5)  
 
p<0.001 
Comparator=40 9.45(2.02) Acupressure to a 
false point (20 
minutes daily for 4 
days+ during 
Frequency of 
nausea 
Intervention = 0(0.75-
0)  
Comparator = 1(2-0)  
p<0.001 
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Study details Participants and treatments Outcome measures and results 
Author, 
year 
(country) 
Study 
Design 
Baseline 
symptom 
severity1 
Number of 
participants  
Gestation 
in weeks 
Mean 
(range) 
Dosage and 
duration 
Primary 
Outcome 
Measures 
Results  
 
p value 
nausea and 
vomiting episodes). 
Acupressure versus vitamin B6 (1 Randomized Clinical Trial) 
Jamigorn 
& 
Phupong, 
200730 
(Thailand) 
Rando
mized 
Clinical 
Trial 
Mild-
moderate 
Intervention=33 
 
6.2(1.0) 
 
Acupressure 
wristbands (Sea-
Bands at P6 point 
worn days 1-5) plus 
placebo tablet  
 
Difference in 
combined 
Rhodes Index 
score 
No difference  p>0.05 
Comparator=33 6.8(1.5) Dummy Sea-Bands 
plus 50 mg tablets 
of vitamin B6 every 
12 h for 5 days. 
Nerve stimulation versus placebo (1 Randomized Clinical Trial) 
Rosen et 
al., 200329 
(USA) 
Multice
ntre 
Rando
mized 
Clinical 
Trial 
Mild-
moderate 
Intervention 
=117 
 
9.2(1.7) 
 
Nerve stimulation 
(for 3 weeks via a 
Relief Band Model 
 
Mean change 
(Confidence 
Intervals) in 
combined 
Rhodes Index 
Score 
Intervention=6.48 
(95% CI 5.31, 7.66)  
Comparator=4.65 
(95% CI 3.67, 5.63)  
p=0.02 
Comparator 
=113 
9.0(1.7) Identical non-
stimulating device 
(for 3 weeks). 
Acupuncture versus placebo (3 Randomized Clinical Trials ) 
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Study details Participants and treatments Outcome measures and results 
Author, 
year 
(country) 
Study 
Design 
Baseline 
symptom 
severity1 
Number of 
participants  
Gestation 
in weeks 
Mean 
(range) 
Dosage and 
duration 
Primary 
Outcome 
Measures 
Results  
 
p value 
Carlsson 
et al., 
200032 
(Sweden) 
Rando
mized 
Crosso
ver 
Study 
Moderate-
severe 
Intervention=17 
 
9.9 (6-16) Acupuncture at 
point PC6 on days 
1 & 2 (for 30 
minutes, 3 times 
daily), no 
acupuncture on 
days 3 & 4 (wash-
out-period) and 
sham acupuncture 
on days 5 & 6 
 
Reduction in 
Visual Analogue 
Scale score for 
nausea 
 
Between pre- and 
post- active 
acupuncture: 
Intervention=4 v 
Comparator=3;  
Between pre- and 
post- placebo 
acupuncture:  
Intervention=0.1 v 
Comparator=1.7  
 
p value not 
reported). 
Comparator=16 Sham acupuncture 
on days 1 & 2, no 
acupuncture on 
days 3 & 4 (wash-
out-period) and 
active acupuncture 
at point PC6 on 
days 5 & 6 (for 30 
minutes, 3 times 
daily). 
Incidence of 
vomiting after 2 
days of 
acupuncture 
Intervention = 7 out of 
17  
Comparator = 12 out 
of 16 women  
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Study details Participants and treatments Outcome measures and results 
Author, 
year 
(country) 
Study 
Design 
Baseline 
symptom 
severity1 
Number of 
participants  
Gestation 
in weeks 
Mean 
(range) 
Dosage and 
duration 
Primary 
Outcome 
Measures 
Results  
 
p value 
Knight et 
al., 200133 
(UK) 
Rando
mized 
Clinical 
Trial 
Mild-
moderate 
Intervention=28 
 
7.8(1.0) 
 
Participants 
allocated to a 
traditional Chinese 
medicine diagnosis 
and treated with 
acupuncture to a 
range of points, 
twice in the first 
week and once 
weekly for two 
weeks) 
 
Median (IQR) 
Visual Analogue 
Scale score  
Intervention: Day 
1=85.5 (71.25-89.75); 
3 days after session 
1=63.0 (50.75-86.5); 3 
days after session 
2=65.0 (36.25-79.5); 3 
days after session 
3=44.0 (29.0-77.25); 3 
days after session 4 
=47.5 (29.25-69.5  
 
Comparator: Day 
1=87.0 (73.0 –90.0); 3 
days after session 
1=69.0 (45.0–87.0): 3 
days after session 
2=61.0 (30.0–80.0); 3 
days after session 
3=53.0 (25.0–80.0); 3 
days after session 4 
=48.0 (14.0–80.0) 
 
p value not 
reported 
Comparator=27 8.0(1.0) Sham treatment 
(tapping a blunt 
cocktail stick, 
supported by a 
plastic guide tube in 
the region of each 
acupuncture point, 
twice in week one 
and once weekly 
for 2 weeks). 
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Study details Participants and treatments Outcome measures and results 
Author, 
year 
(country) 
Study 
Design 
Baseline 
symptom 
severity1 
Number of 
participants  
Gestation 
in weeks 
Mean 
(range) 
Dosage and 
duration 
Primary 
Outcome 
Measures 
Results  
 
p value 
Smith et 
al., 200231 
(Australia) 
Rando
mized 
Clinical 
Trial 
Mild-
moderate 
I=148 
 
Median: 
(IQR)8.3 
(5-13) 
 
 Serin (Japan) 0.2 x 
30 mm needles 
inserted at range of 
points (to 0.5-1 cm 
with maximum of 6 
needles per 
session, then 
manipulated and 
left for a 20-
minutes)  
 
Rhodes index for: 
Nausea 
 
Day 7: 
 i 
Interventions = 
5.0(3.0)  
Comparator = 5.4(3.3)  
Sham = 5.7(2.8)  
Control = 6.1(2.9)  
 
=0.05 
Comparator 
=148 
 
8.3 (4-14) 
 
Acupuncture to p6 
single point only 
(for a 20-minute 
period, twice in 
week 1 then weekly 
for 3 weeks) 
 
Retching 
 
Day 7: I = 1.3(1.4) v C 
= 1.6(1.7) v Sham = 
1.5(1.8) v Control = 
1.7(1.7)  
p>0.05 
 
Sham=148 
 
8.0 (4-13) 
 
Sham acupuncture 
(over similar time 
period) 
 
Vomiting Day 7: 
 Intervention = 1.4(2.0) 
Comparator = 1.2(2.0)  
Sham = 1.5 (2.2)  
Control = 1.5 (2.1)  
p >0.05 
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Study details Participants and treatments Outcome measures and results 
Author, 
year 
(country) 
Study 
Design 
Baseline 
symptom 
severity1 
Number of 
participants  
Gestation 
in weeks 
Mean 
(range) 
Dosage and 
duration 
Primary 
Outcome 
Measures 
Results  
 
p value 
Control=149. 8.4 (5-14) Standardized 
information sheet 
with diet, lifestyle, 
and use of vitamin 
B6 advice plus 
telephone support. 
Vitamin B6 versus placebo (1 Randomized Clinical Trial) 
Vutyavani
ch et al., 
199564 
(Thailand) 
Double 
blind 
Rando
mized 
Clinical 
Trial 
Mild-
moderate 
Intervention 
=173 
 
10.9(2.7) Vitamin B6 tablets 
(10 mg of 
pyridoxine 
hydrochloride 8 
hourly for 5 days)  
Mean change in 
Visual Analogue 
Scale for nausea 
 
Intervention=2.9(2.2)  
Comparator=2.0(2.7)  
 
p<0.001 
Comparator=16
9 
10.9 (2.8) Placebo tablets (8 
hourly for 5 days). 
Mean change in 
episodes of 
vomiting 
Intervention=1.22(2.0) 
Comparator=0.65(2.4) 
(p=0.055). 
p=0.055 
High versus low dose Vitamin B6 versus (1 Randomized Clinical Trial) 
Wibowo et 
al., 201235 
(Indonesia
) 
Rando
mized 
Clinical 
Trial 
Mild I=30 
 
Less than 
12 
 Pyridoxine (5 mg 
mixed with 40 g of 
powdered milk 2 x 
daily for 2 weeks)   
 
Pregnancy 
Unique 
Quantification of 
Emesis and 
nausea  score 
Intervention 
=3.86(2.12) 
Comparator 
=2.80(1.78)  
p<0.05 
Comparator=30 Pyridoxine (0.64 
mg mixed with 40 g 
of powdered milk 
twice daily for 2 
weeks). 
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Table 2b: Summary of findings from trials at low risk of bias evaluating the effectiveness of second –line interventions for nausea and 
vomiting and hyperemesis gravidarum in pregnancy 
Study details Participants and treatments Outcome measures and results 
Author, 
year 
(country) 
Study 
Design 
Baseline 
symptom 
severity1 
Number of 
participants  
Gestation 
in weeks 
Mean 
(range) 
Dosage and 
duration 
Primary 
Outcome 
Measures 
Results  
 
p value 
SECOND-LINE INTERVENTIONS 
Pyridoxine / doxylamine versus placebo (2 Randomized Clinical Trials ) 
Koren et 
al., 201036 
(USA) 
Double 
blind 
Random
ized 
Clinical 
Trial 
Moderate  Intervention 
=140 
 
9.3(2.0) 
 
 
Pyridoxine+ 
doxylamine 
(Diclectin) (2 tablets 
daily up to 4 as 
needed) 
 
Mean change in 
Pregnancy 
Unique 
Quantification of 
Emesis and 
nausea score 
 
Intervention  
=4.8(2.7)  
Comparator 
=3.9(2.6)  
p= 0.006 
 
Comparator 
=140 
9.3(1.8) Placebo tablets (2 
tablets daily up to 4 
as needed). 
Mean area under 
the curve of 
change in 
Pregnancy 
Unique 
Quantification of 
Emesis and 
nausea score 
Intervention 
=61.5(36.9) 
Comparator 
=53.5(37.5)  
p<.0001 
Maltepe & 
Koren, 
201338* 
(Canada) 
Random
ized 
Clinical 
Trial 
Not 
applicable 
Intervention=31 
 
Not 
reported 
Pyridoxine+ 
doxylamine 
(Diclectin) (2 tablets 
daily) following 
pregnancy 
confirmation 
(gradual increase if 
symptoms 
escalate) 
Reduction in 
hyperemesis 
gravidarum 
between 
pregnancies 
 
Intervention =43.3%  
Comparator =17.2%  
p=0.047 
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Study details Participants and treatments Outcome measures and results 
Author, 
year 
(country) 
Study 
Design 
Baseline 
symptom 
severity1 
Number of 
participants  
Gestation 
in weeks 
Mean 
(range) 
Dosage and 
duration 
Primary 
Outcome 
Measures 
Results  
 
p value 
   Comparator=29  Pyridoxine+ 
doxylamine 
(Diclectin) (2 tablets 
daily) once 
symptomatic (with 
gradual increase if 
symptoms 
escalate). 
Pregnancy 
Unique 
Quantification of 
Emesis and 
nausea score ≥11 
Intervention =15.4%   
Comparator = 39.1%  
p<0.04 
Serotonin antagonist (ondansetron) versus pyridoxine / doxylamine (1 Randomized Clinical Trial) 
Oliveira et 
al., 201437 
(USA) 
Double 
blind 
Random
ized 
Clinical 
Trial 
Moderate Intervention=13 
 
Median 
gestation 
(IQR):  
8 (7.1-8.9) 
 
Ondansetron (one 
tablet 4 mg) + one 
placebo tablet 
(every 8 hours for 5 
days) 
 
Median reduction 
in Visual 
Analogue Scale 
for nausea 
 
Intervention = 
51(IQR 37-64)  
Comparator = 
20(IQR 8-51)  
 
p=0.019 
   Comparator=17 Median 
gestation 
(IQR):  
8.1 (7.2-
9.9) 
Pyridoxine (one 
tablet 25 mg) + one 
tablet doxylamine 
(12.5 mg every 8 
hours for 5 days). 
Median reduction 
in Visual 
Analogue Scale 
for vomiting 
Intervention =41(IQR 
17-57)  
Comparator =17(IQR 
-4-38) 
p=0.049 
Psychotherapy v usual treatment (1 Randomized Clinical Trial) 
Faramarzi 
et al, 
201540 
(Iran) 
Random
ized 
Clinical 
Trial 
Moderate;  Intervention=43 
 
Less than 
12  
8 x 50 minute 
psychotherapy 
sessions over 3 
weeks + 40mg 
vitamin B6 
  
Mean change in 
Rhodes Index 
Score combined 
Intervention = 
18.76(5.48) to 
7.06(5.79)  
Comparator = 
19.18(5.63) to 
12.81(6.88)  
p<0.001 
   Comparator=43  40mg vitamin B6  
over 3 weeks 
   
Antihistamines versus placebo (1 Randomized Clinical Trial) 
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Study details Participants and treatments Outcome measures and results 
Author, 
year 
(country) 
Study 
Design 
Baseline 
symptom 
severity1 
Number of 
participants  
Gestation 
in weeks 
Mean 
(range) 
Dosage and 
duration 
Primary 
Outcome 
Measures 
Results  
 
p value 
Erez et 
al., 197139 
(Turkey) 
Random
ized 
Clinical 
Trial 
Mild Intervention=10
0 
 
Less than 
12 
Hydroxyzine 
hydrochloride 
capsules (25mg 2 x 
daily for 3 weeks) 
 
Partial or 
complete relief of 
symptoms 
Intervention = 82% of 
patients 
Comparator = 22% 
patients  
 
p<0.01 
   Comparator=50  Placebo capsules 
(2 x daily for 3 
weeks). 
   
Dopamine antagonists – promethazine versus metoclopramide (1 Randomized Clinical Trial) 
Tan et al., 
201041 
(Malaysia
) 
Double 
blind 
Rando
mized 
Clinical 
Trial 
Moderate Intervention=79 
 
9.2(2.3) 
 
Metoclopramide 
(10 mg IV after 
randomization 
and at 8, 16 and 
24 hours) 
Episodes of 
vomiting 
1.  
Intervention =1 (0–5)   
Comparator =2 (0–3)  
 
p=0.81 
   Comparator=80 9.3(2.6) Promethazine (25 
mg IV after 
randomization and 
at 8, 16 and 24 
hours). 
Visual Analogue 
Scale for nausea 
at 24 hours 
Intervention=2 (1–5)  
Comparator=2 (1–4)  
p=0.99 
Serotonin antagonist (ondansetron) versus metoclopramide (2 Randomized Clinical Trials ) 
Kashifard 
et al., 
201343 
(Iran) 
Double 
blind 
Rando
mized 
Clinical 
Trial 
Mild- 
moderate 
Intervention=49 
 
8.7(2.6) 
 
Ondansetron 
hydrochloride 
tablets (4 mg 3 x 
daily for 1 week. 
Dose gradually 
reduced and 
discontinued after 
2nd week) 
 
Mean Visual 
Analogue Scale 
for nausea 
 
Day 3: 
Intervention = 5,4 
(2.9) 
Comparator = 6.0 
(2.9)  
Day 4:  
Intervention = 4.1 
(2.9)  
Comparator = 5.7 
(2.3)  
p=0.024 
 
p=0.023 
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   Comparator=34 8.7(2.6) Metoclopramide 
(10mg 3 times daily 
for 1 week. Dose 
gradually reduced 
and discontinued 
after 2nd week) 
Episodes of 
vomiting 
Day 3:  
Intervention = 5.3(3) 
Comparator = 
3.2(3.4)  
Day 4:  
Intervention = 5 (3.1) 
Comparator = 3.3(3)  
  
 
 
p =0.006 
 
p = 0.013 
 
 
Abas et 
al., 201442 
(Malaysia
) 
Double 
blind 
Random
ized 
Clinical 
Trial 
Severe Intervention=80 
 
Less than 
or equal to 
16 
Ondansetron (4 mg 
diluted in 100 ml 
normal saline) 
 
VAS for nausea 
(median (IQR)  
Episodes of 
vomiting  
At 8 hours:  
Intervention = 4 (3-6)  
Comparator = 5 (4-
6);  
16hours: Intervention 
= 3 (1-4)  
Comparator = 3(2-
4.75)  
24hours: Intervention 
= 1(1-3)  
Comparator = 2(1-3)  
Repeated 
measures 
analysis of 
variance 
p=0.22 
 
   Comparator=80  Metoclopramide (10 
mg diluted in 100 
ml normal saline). 
Episodes of 
vomiting 
In first 24 hours: 
Intervention=1 (0-2)  
Comparator=2 (0–
2.75)  
p=0.38 
IV fluids D-saline versus N-saline (1 Randomized Clinical Trial) 
Tan et al., 
201344 
(Malaysia
) 
Double 
blind 
Rando
mized 
Clinical 
Trial 
Moderate- 
severe 
Intervention 
=111 
 
9.8(2.8) 
 
5% dextrose–0.9% 
saline by IV 
infusion (125 mL/h 
over 24 hours)  
 
Median vomiting 
episodes 
 
Both groups=0 (0-2)  
 
p=0.66 
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   Comparator 
=111 
9.8(2.5) 0.9% saline by IV 
infusion (125 mL/h 
over 24 hours). 
Both groups also 
given potassium 
chloride (9.5 mmol) 
as required plus 
multivitamin 
(containing 250 mg 
thiamine given IV). 
Nausea score (0-
10) at 24 hrs 
Intervention=2 (1-4)  
Comparator=2 (2-4)  
 
Repeated measures 
analysis of variance 
of nausea score 
p=0.39 
 
  
p=0.046 in 
favour of 
intervention 
group 
Day-case / outpatient (2 Randomized Clinical Trials ) 
McCarthy 
et al., 
201446 
(Ireland) 
Rando
mized 
Clinical 
Trial 
Mild- 
moderate 
Intervention=42 
 
Median 
(IQR):  
8 (7-10) 
 
Treatment in day 
care unit 
(weekdays, 08:00-
16:00). Two litres 
normal saline 
given IV over 5 h. 
Antiemetics as 
required 
 
Hospital stay 
(median IQR) 
Intervention = 0(0-2)   
Comparator = 2(1-4)  
 
  
p<0.001 
   Comparator=56 Median 
(IQR):  
8 (7-11)   
Usual inpatient 
treatment (1 L 
normal saline IV 
over 3 h, then 1 L 
every 6h. 
Antiemetics as 
required). 
   
McParlin 
et al., 
201645 
(UK) 
Random
ized 
Clinical 
Trial 
Moderate-
severe 
Intervention=27 
 
9.3(2.8) 
 
Cyclizine (50 mg IV 
followed by 3 L 
Hartman’s solution 
over 6 hours + 50 
mg of oral thiamine, 
discharged home 
with prescription for 
oral cyclizine (50 
mg 3 times daily) + 
plus ongoing 
support and advice 
Change in 
Pregnancy 
Uniques 
Quantification of 
Emesis and 
nausea score 
Intervention= 6.9(4.1) 
Comparator=6.2(2.3)  
p>0.05 
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   Comparator=26 10.3(2.9) Admission to 
antenatal ward for 
routine care, IV 
fluids, IV cyclizine 
and oral thiamine. 
   
 
Table 2c: Summary of findings from trials at low risk of bias evaluating the effectiveness of third-line interventions for nausea and 
vomiting and hyperemesis gravidarum in pregnancy 
Study details Participants and treatments Outcome measures and results 
Author, 
year 
(country) 
Study 
Design 
Baseline 
symptom 
severity3 
Number of 
participants  
Gestation 
in weeks 
Mean 
(range) 
Dosage and 
duration 
Primary 
Outcome 
Measures 
Results  
 
p value 
THIRD-LINE INTERVENTIONS  
Corticosteroids versus placebo (1 Randomized Clinical Trial) 
Nelson-
Piercy et 
al., 200147 
(UK) 
Rando
mized, 
double 
blind, 
placebo
-
controll
ed trial 
Moderate
-severe 
Intervention=12 
 
0.6(2.1) 
 
One week course 
of prednisolone 
tablets (20 mg 12 
hourly)   
Both groups: if 
symptomatic after 
72 hours, therapy 
was changed to IV 
equivalent. 
Episodes of 
vomiting median 
(range)  
 
 
Vomiting > 5 
times /day at one 
week 
 
Number 
participants:  
Intervention=5, 
Comparator=7,  
Relative risk (95% 
CI) =1.4 (0.6-3.2)  
 
Intervention=2, 
Comparator=5,  
p not 
reported 
                                                 
3 Symptom severity was classified by two independent assessors (CMP and SCR) as either mild, moderate or severe, based on the description of severity reported in the study inclusion criteria and, 
if available, any severity score provided at baseline. 
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Relative risk (95% 
CI) =2.5 (0.6-10.5). 
 
   Comparator=13 8.3(1.9) One-week course 
of placebo tablets 
(20 mg 12 hourly.  
Both groups: if 
symptomatic after 
72 hours, therapy 
was changed to IV 
equivalent. 
Visual Analogue 
Scale for vomiting 
median (range) 
 
 
Visual Analoge 
Scale for nausea 
median (range) 
Intervention  = 
2.0 (-1.0-4.0), 
Comparator  = 
1.5 (-3.0- 4.0)  
 
 
Intervention =6.5 
(2.0-10.0),  
Comparator=4.0 (-
5.0- 9.0), Relative 
risk 0.10 for 
proportion with 
nausea  
 
 
Corticosteroids versus Phenothiazines / promethazine / Phenergan (1 RCT) 
Safari et 
al., 
199848 
(USA) 
Rando
mized 
Clinical 
Trial 
Moderate
-severe 
Intervention=20 
 
9.8(2.1) 
 
Methylprednisolo
ne (16 mg orally 3 
x daily for 3 days, 
followed by a 
tapering regimen, 
halving of dose 
every 3 days, to 
none during the 
course of 2 
weeks) 
 
Improvement of 
symptoms or 
therapy failure 
within 2 days of 
starting therapy. 
  
 Intervention = 
therapy failure in 3 
patients   
Comparator = 
therapy failure in 2 
patients  
 
p not 
reported 
   Comparator=20 9.5(2.7) Promethazine (25 
mg orally 3 times 
daily for 2 weeks). 
Readmitted to 
hospital 
Intervention = 0 
patients  
Comparator = 5 
patients  
p=0.0001 
Corticosteroids versus metoclopramide (1 Randomized Clinical Trial) 
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Bondok 
et al., 
200649 
(Egypt) 
Prospe
ctive, 
double 
blind 
study 
Moderate
-severe 
Intervention=20 
 
10(2.68) 
 
IV hydrocortisone 
(300 mg for 3 
days, followed by 
a tapering 
regimen. 3 x 10 
mL syringes, 
every 8 hrs, 1 x 
drug diluted in 
normal saline, 2 x 
normal saline) 
 
Mean episodes 
of vomiting 
Intervention = 
reduced 40.9% on 
Day 2; 71.6% on 
day 3; 95.8% on day 
7  
 
Comparator = 16.5% 
on day 2; 51.2% on 
day 3; and 76.6% 
on day 7  
p<0.001 
 
   Comparator=20 11(2.44) Metoclopramide (10 
mg in 10-mL 
syringe diluted in 
normal saline via IV 
every 8 hrs for the 
same 7-day 
period). 
   
Transdermal clonidine (1 Randomized Clinical Trial) 
Maina et 
al., 
201450 
(Italy) 
Double 
blind, 
controll
ed, 
cross-
over 
Rando
mized 
Clinical 
Trial 
Severe 12 in total 6 to 12 Transdermal 
clonidine patch (5 
mg) 5 day period 
before cross over. 
Other antiemetic 
drugs and IV 
fluids as needed 
plus thiamine  
supplement 
Mean Pregnancy 
Unique 
Quantification of 
Emesis and 
nausea score 
(95% CI) 
 
Intervention =6.3 
(5.5–7.1) 
Comparator = 8.5 
(7.7–9.3)  
 
p=0.001 
     Sham patch 5 day 
period before cross 
over. 
Other antiemetic 
drugs and IV fluids 
as needed plus 
thiamine  
supplement 
Mean Visual 
Analogue Scale 
score (95% CI) 
Intervention = 
22 (19–26)  
Comparator = 
29 (25–32)  
p=0.009 
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Table 3: Grade of evidence and recommendation  
Treatment1 Number of Studies2 Risk of bias / quality AHA Rating 
 First-line treatments for mild-moderate nausea and vomiting in pregnancy 
Ginger 
 17 Randomized clinical 
trials 
 
 10 = low17-25;  
3 = unclear65-67; 
4 = high 68-71 
Level A Class IIa 
Acupressure 
 10 Randomized clinical 
trials 
 
 5 = low25-28,30;  
4 = unclear72-75;  
1 = high76 
 
Level A Class IIa 
 1 case series  1 = weak77 
Nerve Stimulation 
 3 Randomized clinical 
trials 
 1 = low29;  
2 = unclear78,79 
Level B Class IIb 
Acupuncture 
 6 Randomized clinical 
trials 
 3 = low31-33;  
3 = high80-82 
Level A Class IIb 
Aromatherapy 
 2 Randomized clinical 
trials 
 2 = unclear83,84 Level B Class IIb 
Vitamin B6 
(pyridoxine) 
 14 Randomized clinical 
trials 
 7 = low20-23,30,34,35;  
4 = unclear66,85-87;  
3 = high69,70,88 
Level A Class IIa 
 
Second-line treatments for moderate-severe nausea and vomiting in pregnancy or 
hyperemesis gravidarum 
Psychotherapy 
 1 Randomized clinical 
trial 
 1 = low40 Level B Class IIa 
Vitamin B6 
(pyridoxine) / 
doxylamine 
combination 
5 Randomized clinical 
trials  
 4 = low24,36-38;  
1 = unclear89 
 Level A Class IIa 
 1 case-control study 
 1 cohort-analytic 
 1 = weak90 
 1 = moderate91 
Antihistamines 
 7 Randomized clinical 
trials 
 
 1 = low39;  
4 = unclear67,87,92,93;  
2 = high88,94 
Level B Class IIa 
Dopamine 
antagonists 
 10 Randomized clinical 
trials 
 
 5 = low41-43,48,49;  
3 = unclear95-97;  
2 = high71,80 
 
Level A Class IIa 
 1 case-control study 
 1 cohort study 
 1 = weak90 
 1 = weak98 
Serotonin 
antagonists 
 7 Randomized clinical 
trials 
 
 3 = low37,42,43;  
4 = unclear89,92,93,95 
 Level A Class IIa 
 1 cohort analytic study  1= weak99 
Intravenous fluids 
 1 Randomized clinical 
trial 
 1 = low44 Level B Class IIa 
Intravenous fluids 
with or without 
Diazepam 
 1 Randomized clinical 
trial 
 1 = unclear100 Level B Class III 
                                                 
1 Includes treatments excluded from the narrative summary due to the particularly low quality of available 
evidence (aromatherapy, intravenous fluids with or without Diazepam, gabapentin and nasogastric / assisted 
feeding. 
2 Number of studies includes all those with an appropriate treatment group (either intervention or comparator). 
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Out-patient / day-
case management 
 2 Randomized clinical 
trials 1 case series study 
 2 = low45,46 
 1 = weak101 
Level A Class IIa 
 
Third-line treatments for moderate-severe nausea and vomiting in pregnancy or 
hyperemesis gravidarum 
Corticosteroids 
6 Randomized clinical 
trials  
 3 = low47-49;  
2 = unclear96,97;  
1 = high102 Level A Class IIb 
 1 case series  1 = weak103 
Nasogastric / 
assisted feeding 
 2 case series 
 1 cohort analytic 
 2 = weak104,105 
 1 = moderate106 
Level C Class IIb 
Gabapentin  1 case series  1 = weak107 Level C Class III 
Transdermal 
clonidine 
 1 Randomized clinical 
trial 
 1 = low50 Level B Class IIb 
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Table 1: Dose, common side effects and contra-indications of recommended therapies by severity of NVP 
and HG3 
Therapy Dose Side effects Contra-indications 
Severity of symptoms: MILD 
Ginger Most common regime: 250mg 
every 6 hours  
Acid reflux None apparent 
Vitamin B6 
(pyridoxine) 
10-25mg every 8 hours Drowsiness; decreased 
sensation to touch, 
temperature, and vibration; 
loss of balance or coordination. 
 
Antihistamines 
e.g. Cyclizine  
50mg every 8 hours Drowsiness; dizziness; muscle 
twitches; dry mouth; headache; 
skin rash; tachycardia. 
Glaucoma, high or low blood 
pressure, epilepsy,  
Severity of symptoms: MODERATE 
Antihistamine/ 
vitamin B6 
combination 
(doxylamine/ 
pyridoxine) 
10mg doxylamine + 10mg 
pyridoxine up to 4 times 
daily if needed 
Drowsiness; somnolence; 
dizziness; nervousness; stomach 
pain; headache; diarrhoea; 
irritability; insomnia. 
Taking monoamine oxidase 
inhibitors, antimuscarinic drugs 
Metoclopramide 10mg every 8 hours Dystonic movements; oculogyric 
crises; diarrhoea; drowsiness; 
restlessness; irritability; dry 
mouth; insomnia; urinary 
problems; depression; skin rash. 
Kidney or liver disease, 
congestive heart failure, high 
blood pressure, diabetes, 
history of depression, epilepsy 
(or other seizure disorder) 
Promethazine 25mg every 8 hours Dizziness; drowsiness; excitation;  
skin rash;  
increased sensitivity of skin to 
sunlight;  
lack of coordination; loss of 
strength or energy; muscle pain or 
weakness; insomnia. 
Should be used with caution in 
persons with seizure disorders 
or in persons who are using 
concomitant medications, such 
as narcotics or local 
anaesthetics, which may also 
affect seizure threshold. 
Ondansetron 4mg every 8 hours Anxiety; dizziness; constipation; 
dry mouth; confusion, headache; 
hyperventilation; tachycardia; 
irritability; restlessness; muscle 
spasms; insomnia. 
Cardiac arrhythmias, history of 
prolonged QT interval, heart 
failure, hypokalaemia, 
hypomagnesemia, use of 
concomitant medications that 
lead to prolongation of QT 
interval. 
Severity of symptoms: SEVERE 
Ondansetron 4-8 mg every 8 hours As above As above 
Corticosteroids Hydrocortisone 100mg i.v. 
twice daily, converting to 
oral prednisolone 40-50mg 
daily with the dose gradually 
tapered until the lowest 
maintenance dose is reached. 
Increased risk of infections; 
gestational diabetes mellitus. 
Systemic infections, unless 
specific anti-infective therapy is 
employed. Live virus 
immunization. Hypersensitivity 
to any component. 
 
 
                                                 
3 Data obtained from searches of appropriate drug and therapeutic websites. 
